Clinical trial Phase 3 Interventional Ages 18 and up

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Run by AstraZeneca · NCT05120349 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2027-08-02.

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment390 (actual)
SponsorAstraZeneca
Industry-sponsored
Drugs / interventionsOsimertinib, Placebo
Locations139 sites (Argentina, Brazil, Canada, China, Germany, Italy, Japan, Malaysia and more)
Trial IDNCT05120349 on ClinicalTrials.gov

What this trial studies

This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R). Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

1. Male or female, at least ≥ 18 years.
2. NSCLC, of non-squamous histology.
3. Stage IA2 or IA3 disease, based on TNM8 classification.
4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection.
5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
6. World Health Organization performance status of 0 or 1.
7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.
9. Minimum life expectancy of \> 6 months.
10. Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.

Exclusion Criteria

1. Mixed small cell and non-small cell cancer history.
2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection.
3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including HCV and HIV or active uncontrolled HBV infection.
4. History of another primary malignancy, including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
5. Any of the following cardiac criteria:

   * Mean resting QTcF interval \> 470 ms, obtained from triplicate ECGs performed at screening.
   * Any abnormalities in rhythm, conduction, or morphology of resting ECG,
   * Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events.
6. History of interstitial lung disease.
7. Inadequate bone marrow reserve or organ function.
8. Any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study intervention.
9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
11. Participants currently receiving medications or herbal supplements known to be strong inducers of CYP3A4.

Where it's running

  • Research Site
    Anchorage, Alaska, United States
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Orange, California, United States
  • Research Site
    Grand Junction, Colorado, United States
  • Research Site
    Newark, Delaware, United States
  • Research Site
    Atlanta, Georgia, United States
Show 44 more locations
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Frederick, Maryland, United States
  • Research Site
    Morristown, New Jersey, United States
  • Research Site
    Flushing, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    White Plains, New York, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Fort Belvoir, Virginia, United States
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Caba, Argentina
  • Research Site
    Cipolletti, Argentina
  • Research Site
    La Plata, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    S.C. de Bariloche, Argentina
  • Research Site
    Barretos, Brazil
  • Research Site
    Belo Horizonte, Brazil
  • Research Site
    Porto Alegre, Brazil
  • Research Site
    Recife, Brazil
  • Research Site
    Rio de Janeiro, Brazil
  • Research Site
    São Paulo, Brazil
  • Research Site
    São Paulo, Brazil
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Toronto, Canada
  • Research Site
    Beijing, China
  • Research Site
    Beijing, China
  • Research Site
    Beijing, China
  • Research Site
    Beijing, China
  • Research Site
    Beijing, China
  • Research Site
    Beijing, China
  • Research Site
    Changchun, China
  • Research Site
    Changsha, China
  • Research Site
    Changsha, China
  • Research Site
    Chengdu, China
  • Research Site
    Fuzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Guangzhou, China
  • Research Site
    Hangzhou, China
  • Research Site
    Harbin, China
  • Research Site
    Jinan, China
  • Research Site
    Nanjing, China
  • Research Site
    Shanghai, China

+89 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Jonathan Goldman, MD — University of California, Los Angeles

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.